# Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

> **NCT05151848** · PHASE4 · UNKNOWN · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 100 (estimated)

## Conditions studied

- Takayasu Arteritis

## Interventions

- **DRUG:** Adalimumab Injection
- **DRUG:** Tofacitinib 5 MG

## Key facts

- **NCT ID:** NCT05151848
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-05
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05151848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05151848, "Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05151848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*